Clinical Trial Update: Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study [Phase 2]

View source ↗

Summary

This update covers the Phase 2 SANO-3 trial evaluating nivolumab during active surveillance after neoadjuvant chemoradiation in esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Esophageal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING